THE LITERATURE contains only
|
|
- Claude Raymond Howard
- 5 years ago
- Views:
Transcription
1 SOCIOECONOMICS AND HEALTH SERVICES SECTION EDITOR: PAUL P. LEE, MD Estimates of Incidence Rates With Longitudinal Claims Data Frank A. Sloan, PhD; Derek S. Brown, MA; Emily S. Carlisle, MA; Jan Ostermann, PhD; Paul P. Lee, MD, JD Objective: To estimate incidence rates of the 3 major chronic eye diseases diabetic retinopathy (DR), glaucoma, and age-related macular degeneration (ARMD) by using longitudinal claims data from Medicare. Methods: Longitudinal cases were ascertained by using a national probability sample of Medicare beneficiaries aged 65 years and older in 1991 who initially had none of the eye diseases documented. After adjusting for death and enrollment in a health maintenance organization, claims filed by optometrists or ophthalmologists with an International Classification of Diseases, Ninth Revision, Clinical Modification code for all forms of DR, glaucoma, and ARMD were used to indicate diagnosis. Results: Annual incidence rates for the 3 conditions after the first year of observation ranged from 14.3% to 17.7% (higher earlier) across an 8-year longitudinal follow-up. Incidence rates among those with diabetes mellitus for any form of DR varied between 3.8% and 6.5%, while those for glaucoma varied between 4.6% and 7.8% and those for ARMD varied between 7.5% and 9.3%. Conclusions: Longitudinal claims data after the first year provide relatively stable estimates of incidence rates on an annual basis. These estimates are comparable with those of the few population-based studies available. Arch Ophthalmol. 2003;121: From the Department of Economics (Dr Sloan, Mr Brown, and Ms Carlisle); Center for Health Policy, Law, and Management (Drs Sloan and Ostermann); and Department of Ophthalmology, School of Medicine (Dr Lee), Duke University, Durham, NC. The authors have no relevant financial interest in this article. THE LITERATURE contains only limited information on the incidence of the major eye diseases, or even chronic diseases more generally. Longitudinal surveys exist only for specific geographically circumscribed populations (eg, Beaver Dam, 1 Blue Mountains, 2 Barbados, 3,4 Wisconsin 5 ), are costly and effort intensive, and have limited external validity. They require recruitment, efforts to promote retention of the subjects, and physical examinations all reasons for limiting their scope. High costs of data acquisition limit sample size and diminish ability to obtain adequate numbers for reliable estimates of annual incidence rates, which is an especially serious consequence for certain groups of interest, such as the oldest and racial minorities. In this study, we used longitudinal Medicare claims data from 1991 through 1999 to estimate annual incidence rates for the 3 major eye diseases: diabetic retinopathy (DR), glaucoma, and age-related macular degeneration (ARMD). Because the data were from the same cohort of Medicare beneficiaries, we were able to examine the stability of incidence estimates. Further, we were able to adjust rates to compare them with currently available population-based incidence rates to determine the relative rates obtained with different methods. METHODS OVERVIEW The study population consisted of the same nationally representative sample of Medicare beneficiaries that was used to estimate the prevalence of DR, glaucoma, and ARMD in a cohort of Medicare beneficiaries between 1991 and 1999, as in our previous article. 6 The methods described in this section specifically pertain to our analysis of incidence rates. INCIDENCE RATES We specified disease onset by using the earliest diagnosis code found in the claims. Once an individual was identified as having a particular disease, he or she remained in a disease cohort for the remainder of the analysis but was excluded from subsequent analysis of incidence rates. For a case to be identified as incident, the beneficiary had to have undergone an eye examination with an ophthalmologist or optometrist during the year or undergone a procedure with an ophthalmological procedure code. For each year, we began with the number of persons who did not have a disease diagnosed previously; deter- 1462
2 Table 1. Definition of Eye s Panel A: All Persons CPT-4 or ICD-9-CM Procedure Codes Restrictions None 92002, 92004, 92012, 92014, 92018, 92019, 92225, 92226, 92230, 92235, 92250, With provider code 18 or 41 only (optometrist or 99024, 99025, , , , ophthalmologist) on claims where available. If unavailable, , , , with only ICD-9-CM diagnosis codes 360.x-379.x. None 16.21, 95.02, 95.03, 95.11, Panel B: Diseases Diseases Diabetes with any ocular complication , 76516, 67208, 67210, 67227, Diabetes with any form of DR Diabetes, claims with only as primary diagnosis 67036, , 67101, 67105, , Glaucoma, any form 92020, , 92100, 92120, 92130, 92140, 92275, 65850, 65855, 66150, 66155, 66160, 66165, 66170, 66172, 66180, 66184, 66185, 66700, 66710, 66720, Glaucoma, narrow-angle only 65865, 65870, 65880, 66500, 66505, 66600, 66625, 66630, 66761, Glaucoma, other 92287, 65900, ARMD, any form 92240, 92283, 92284, 67208, 67210, 67218, ARMD, wet only (362.52, ) 67036, 67038, 67039, 67040, 67108, 67110, 67220, Abbreviations: ARMD, age-related macular degeneration; CPT-4, Current Procedural Terminology, Fourth Edition; DR, diabetic retinopathy; ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification. mined whether the person had undergone an eye examination during the year; and, conditional on the person having undergone an eye examination, determined whether the disease was diagnosed. We allowed for disease progression into subgroups. We also calculated transitions to a more severe condition within each major eye disease category. For example, once a person with diabetes with background DR (BDR) had a claim with proliferative DR (PDR), we moved the individual into the subgroup of those with diabetes with PDR. Additionally, we allowed for coexistence among the 3 diseases. Annual disease-specific incidence rates were calculated by using a denominator of the number of persons alive and not in a health maintenance organization (HMO) for 6 or more months during the year who underwent eye examination. Because of concerns that incidence rates based only on the number of persons with examinations may be biased, we also conducted a sensitivity analysis. We assumed a rate of eye disease in the unexamined population that was 50% of the rate of those who underwent eye examination in the same year. Alternatively, we assumed a 0% incidence rate in the unexamined population, yielding the lowest possible bound on total incidence. We thus calculated estimated lower bounds to incidence that were weighted averages of the 2 populations (unexamined and examined). We identified eye examinations by using Current Procedural Terminology, Fourth Edition and International Classification of Diseases, Ninth Revision, Clinical Modification procedure codes. For individuals without any eye disease, we used the codes shown in panel A in Table 1. Any instance of 1 or more codes on a claim was counted as an eye examination. For the subsample with 1 or more of the 3 eye diseases, we used additional disease-specific codes to identify other forms of contact with an eye-care provider during the analysis interval (Table 1, panel B). RESULTS In 1991, 31.2% of beneficiaries without diagnoses underwent eye examination (Table 2). Of these persons, 29.6% had at least 1 disease diagnosed: 1.8% had DR, 17.1% had glaucoma, and 12.7% had ARMD. In 1992, an almost identical percentage (32.9%) of persons without diagnoses underwent examination, with an overall yield of newly diagnosed cases of 17.7%: 1.3% had DR, 7.9% had glaucoma, and 9.4% had ARMD. By 1999, the number of beneficiaries with undiagnosed disease who underwent eye examination had increased to 38.9%, and the number of persons alive, not in HMOs, and without diagnosed disease decreased considerably, to less than one third of the 1991 number. During these years, annual incidence rates did not differ dramatically within disease category after the initial 2 years. Incidence of DR is conditional on diabetes having been diagnosed. Thus, despite attrition due to mortality and diagnosis of DR, the number of patients with diabetes and no previous DR diagnosis increased until 1993, as a result of more cases of diabetes but not of DR being diagnosed, and declined monotonically thereafter (Table 3). This change did not occur in Table 2 because all Medicare beneficiaries in the sample were included in the denominator. The percentage of those with diabetes with undiagnosed DR who underwent eye examination in each year increased across time. By 1999, the rate was 54.5%. Most patients had DR diagnosed at an early stage (BDR). Diagnosing PDR as the first DR diagnosis was relatively rare and occurred even less frequently across time. The annual incidence rate of BDR declined as eye examination rates increased. At baseline, individuals in our sample did not have glaucoma diagnosed (Table 4). By 1999, because of deaths, movement into an HMO, and diagnosis of glaucoma, only 7988 did not have glaucoma diagnosed. The percentage of persons with no diagnosed glaucoma who underwent eye examination increased appreciably across time, from 31.4% in 1991 to 44.2% in However, incidence rates decreased across time. After the first
3 Table 2. Eye s Among Persons With Disease and Incidence of DR, Glaucoma, and ARMD by * No. of Persons Without DR, Glaucoma, or ARMD Diagnosed Cases Remaining Persons Who Underwent Eye Cases Diagnosed DR Glaucoma ARMD Any of the 3 Diseases Abbreviations: ARMD, age-related macular degeneration; DR, diabetic retinopathy. *Excludes persons who died prior to July 1 in any given year and those who were in a health maintenance organization for at least 6 months during the year. The percentage of DR, glaucoma, and ARMD diagnoses adds up to more than the percentage of cases of any of the 3 diseases because of multiple diagnoses per person. Table 3. Eye s Among Persons With Disease and Incidence of DR by * No. of Persons With Diabetes Without DR Diagnosed Cases Remaining Persons Who Underwent Eye Persons With DR Diagnosed Unspecified Background Proliferative Abbreviation: DR, diabetic retinopathy. *Excludes persons who died prior to July 1 in any given year and those who were in a health maintenance organization for at least 6 months during the year. Table 4. Eye s Among Persons With Disease and Incidence of Glaucoma by * No. of Persons Without Glaucoma Diagnosed Cases Remaining Persons Who Underwent Eye Persons With Glaucoma Diagnosed NAG POAG Other Suspected Abbreviations: NAG, narrow-angle glaucoma; POAG, primary open-angle glaucoma. *Excludes persons who died prior to July 1 in any given year and those who were in a health maintenance organization for at least 6 months during the year. years, most of the new diagnoses were for suspected glaucoma, followed by primary open-angle glaucoma (POAG). Narrow-angle glaucoma (NAG) was diagnosed about one fourth as frequently as was POAG. In 1991, beneficiaries did not have ARMD diagnosed (Table 5). As with glaucoma, the number of persons without a diagnosis remaining in the sample declined markedly during the observation period. The per- 1464
4 Table 5. Eye s Among Persons With Disease and Incidence of ARMD by * No. of Persons Without ARMD Diagnosed Cases Remaining Persons Who Underwent Eye Persons With ARMD Diagnosed Unspecified Dry Wet Abbreviation: ARMD, age-related macular degeneration. *Excludes persons who died prior to July 1 in any given year and those who were in a health maintenance organization for at least 6 months during the year. Table 6. Annual and Long-term Transitions to PDR, Glaucoma, and Wet ARMD No. of Persons With Unspecified DR or BDR Glaucoma ARMD DR Glaucoma Wet ARMD PDR Diagnosis, % No. of Persons Diagnosis, % No. of Persons Diagnosis, % With Suspected With Dry or In By 1999 Glaucoma In By 1999 Unspecified ARMD In By Abbreviations: ARMD, age-related macular degeneration; BDR, background diabetic retinopathy; DR, diabetic retinopathy; PDR, proliferative diabetic retinopathy. centage of persons without ARMD diagnosis who underwent eye examination increased across this period. In 1992, 3.0% of persons who underwent eye examination had a diagnosis of dry ARMD; incidence rates for dry ARMD reached a peak in 1998 at 4.6%. A first-time diagnosis of wet ARMD was relatively rare but did occur in approximately 1.0% of previously undiagnosed cases. The severity of eye disease progressed for many individuals in our sample (Table 6). For DR, between 1992 and 1999, rates of first diagnosis of PDR varied from 1.4% to 4.0%. Of the cohort of 118 persons with diabetes with unspecified DR or BDR who were examined in 1992, 4 (3.4%) had a diagnosis of PDR in Of these 118 persons, 16 (13.6%) eventually had a diagnosis by For glaucoma, transitions to POAG or NAG from suspected glaucoma were appreciably higher than for transitions from less severe forms of DR to PDR. For ARMD, only about 2% of persons with dry or unspecified ARMD progressed to wet ARMD in a given year. However, across time, rates of progression to wet ARMD in this aging population were substantial. For those with a dry or unspecified ARMD diagnosis in 1992, 2.1% of persons who underwent eye examination had a diagnosis of wet ARMD in that year. However, by 1999, 12.7% of persons with other forms of ARMD had progressed to wet ARMD. We assessed our findings sensitivity to the definition of the denominator. Assuming that the unexamined population had an incidence rate half that of the examined population, our mean estimated lower bounds were 3.7% vs 5.1% for DR, 4.2% vs 6.2% for glaucoma, and 5.9% vs 8.3% for ARMD (Table 7). Alternatively, substituting an assumed incidence rate of 0% for the unexamined sample, the mean absolute estimates of lower bounds were 2.4% for DR, 2.3% for glaucoma, and 3.5% for ARMD. COMMENT The onset of major eye diseases in an older population is a common occurrence, as is progression of these diseases. In this analysis of Medicare data, we found that the annual incidence rates among Medicare beneficiaries ranged from 3.8% to 6.5% for DR for persons aged 65 years and older who had a diagnosis of diabetes mellitus, 4.6% to 7.8% for glaucoma, and 7.5% to 9.3% for ARMD. These estimates are left-censored in that some individuals had developed at least 1 of the 3 eye diseases 1465
5 Table 7. Sensitivity Analysis Percentages Disease Mean Estimated Incidence Mean Lower-Bound Incidence of 50%* Mean Lower-Bound Incidence of 0% DR Glaucoma ARMD Abbreviations: ARMD, age-related macular degeneration; DR, diabetic retinopathy. *Assumes the incidence in the unexamined population is 50% of the incidence in the examined population. Assumes the incidence in the unexamined population is 0% of the incidence in the examined population. prior to the beginning of the study. All rates for 1991, and to some extent the next year, were artificially high because these estimates for the initial year reflected prevalence and incidence. For this reason, rates for 1993 through 1999, when the rates more likely reflect incidence alone, are more valid. Only a minority of Medicare beneficiaries underwent eye examination in a given year, although the percentage of persons without a previous diagnosis who underwent examination increased across time. On average, 53% of persons with a diagnosis of diabetes did not undergo eye examination in any given year after diagnosis, which is far short of the American Academy of Ophthalmology and American Diabetes Association recommendations of eye examinations at diagnosis with annual follow-ups As a greater percentage of persons with diabetes without a DR diagnosis underwent eye examinations each year, the incidence rate of DR decreased. One interpretation is that undergoing eye examination is indicative of better glucose control. However, in contrast to DR incidence rates, conditional on undergoing examination, incidence rates for glaucoma and ARMD in this cohort of beneficiaries were high, measured both in terms of first diagnosis of a particular eye disease and progression (see the following comparison with other studies). Of those individuals still alive in 1999, only 15% had not undergone eye examination during the study. Our national estimates of incidence rates were based on physician diagnoses as reported on Medicare claims rather than on the explicit diagnostic criteria used in the population-based studies (Table 8). To compare our estimates with those of population-based studies, we normalized the other studies estimates to our population s age distribution, then aggregated our incidence rates to match the cumulative rates in other studies. To determine incidence rates across multiple years, all possible periods were calculated to provide a range of estimated incidence rates (eg, to compare with 4-year incidence estimates, we aggregated years 1992 through 1995, 1993 through 1996, and so on). For 2 studies (Denmark 11,12 and San Luis Valley 13 ) in which age ranges included young people, we were unable to adjust for age owing to lack of information about the study population s age distribution. The incidence rates for DR in our study were generally in the same range as those of previous studies, although the rates in the other studies varied markedly around the mean difference of 0.4% (Table 8, panel A). The age-adjusted aggregate 4-year incidence rate from the Wisconsin Epidemiological Study on Diabetic Retinopathy 5 was 37%, and for the San Luis Valley study, 13 the 4-year unadjusted rate was 22.5%. In contrast, our 4-year aggregate incidence rates averaged 19.1%, with a range of 23.0% ( ) to 16.0% ( ). Our estimates were high compared with those of the Framingham study 14 roughly 5% in the Framingham study, as compared with our mean of 23.7% and range of 27.4% (earliest) to 20.2% (latest) for 5-year incidence rates. Our estimates were similar to those of the study conducted in Denmark, 11,12 with 4.3% per year in Denmark, not adjusted for age, as compared with a mean of 5.4% and range of 6.5% (earliest) to 4.3% (latest). One reason for lower estimates of DR incidence rates is that providers sometimes miss PDR and BDR, depending on the diagnostic method used. 15 Also, if a comparison study had a higher proportion of participants with insulin-independent diabetes than there was in our study, we would expect to see a higher incidence rate for complications such as DR. Our estimates were much higher than the Framingham estimates, but the authors of that study acknowledged that its prevalence rates were much lower than previously published estimates. 14 Available comparison estimates for glaucoma were limited to POAG. Our incidence rates of POAG were slightly higher than those in other studies (Table 8, panel B). The 4-year incidence rate determined from the Barbados Eye Study, 3,4 with a black population, normalized to our population was approximately 4.5%. The mean of our 4-year rates was 8.2%, with a range of 10.3% (earliest) to 6.0% (latest). Our mean 5-year incidence rate was 9.8%, with a range of 11.7% (earliest) to 8.5% (latest); in contrast, the age-normalized Melbourne 5-year incidence rate 16 was about 8%, and the normalized Framingham 14 5-year incidence rate was about 1%. The comparison estimates for this disease were for highly specific definitions of POAG, which partially explains the gap. Clinicians in the community may overdiagnose glaucoma; one study indicated that about 50% of patients receiving glaucoma medications on a longterm basis had only elevated pressures documented, without documentation of either optic nerve or visual field changes or damage. 17 We also computed incidence rates restricting the definition of POAG (not shown), which lowered our estimates by 15%. Another potential reason for the difference is that our cohort was much older than that in the other studies. Those studies showed a dramatic increase as the population aged, which would be consistent with higher estimates for the older persons in our study. In the comparison studies, individuals in their late 70s and 80s were at the high end of the age distribution, in samples already limited in size, whereas in our sample, the median age was 74 years in 1991 and 81 years in Our estimates of incidence rates for ARMD were high, as compared with those in other studies (Table 8, panel C). The age-adjusted 2-year incidence rate for the Rotterdam study 18 was less than 1%; our mean incidence rate was 16.0%, with a range of 17.0% (earliest) to 15.1% (latest). Our 5-year incidence rate was 33.0%, with a range of 34.7% (earliest) to 32.3% (latest). The Blue Moun- 1466
6 Table 8. Comparison of Cumulative Incidence Rates With Those in Other Epidemiological Studies of Eye Disease Comparison Studies Rates Normalized to Our Age Distribution, % Our Study s Cumulative Incidence Rates, %* Study Period, y Population Mean Range Difference Panel A: DR Wisconsin 5 4 Mostly white Framingham 14 5 Mostly white Denmark 11,12 1 White 4.3 NA San Luis Valley 13 4 White, Hispanic 22.5 NA Panel B: Open-angle Glaucoma Barbados 3 4 Black Barbados 4 4 Black Melbourne 16 5 White Framingham 14 5 Mostly white Panel C: ARMD Rotterdam 18 2 White Blue Mountains 2 5 White Framingham 14 5 Mostly white Beaver Dam 1 5 Mostly white Abbreviations: ARMD, age-related macular degeneration; DR, diabetic retinopathy; NA, not applicable. *Our annual incidence was aggregated across a period the same length as that in the comparison study. All possible periods were calculated (eg, , , and so on). Highest and lowest cumulative incident rates correspond to the earliest ( xx) and latest (19xx-1999) periods, respectively. Our study s mean minus the mean of the comparison study s normalized rates. Mean difference in our study relative to that in the comparison studies in panel A was 0.4, in panel B was 4.5, and in panel C was Studies did not publish age distributions; estimates are not normalized to our population. Age range for Denmark was 3 to 92 years and for San Luis Valley was 20 to 74 years. Early ARMD only. tains, 2 Framingham, 14 and Beaver Dam 1 studies had incidence rates lower than 23%. Variation in diagnostic criteria accounts for some of this difference, because clinicians might diagnose even a few drusen as ARMD. In contrast, population-based studies, on which the comparison estimates are based, tend to have strict criteria for ARMD diagnosis that often require more than the presence of drusen. For example, the Framingham study 14 required that senile macular degeneration entirely account for loss in visual acuity to 20/30 or worse for the case to be counted as incident. Although guidelines for clinicians exist, individual professional judgment varies, and criteria for diagnosis may be less stringent on the whole. Changes in Medicare financial incentives and resulting changes in coding are not likely to influence our incidence rates on average, because such changes would have had to occur throughout this period and influence our incidence estimates each year. Another consideration is that our sample included individuals who were institutionalized; those in nursing homes may be expected to have higher rates of eye disease than do the elderly living in the community. Finally, as with the glaucoma studies, our population was older than those of the previous ARMD studies, and ARMD tends to increase dramatically with age. Our incidence rates could be overstated for 2 reasons. First, as mentioned earlier, in the first year and perhaps the next year, we captured prevalent and incident cases. Second, selection could lead to overstatement. We excluded persons in HMOs for more than 6 months during a year, but they reentered our analysis when they switched back to fee-for-service programs. If patients in HMOs are healthier, we might have overstated incidence rates for Medicare beneficiaries overall. The literature offers mixed opinions on whether patients in HMOs are indeed healthier; the prevalent findings are that enrollees in Medicare HMOs tend to be healthier, 19,20 although no such conclusion is supported in the private insurance sector More comprehensive coverage of vision services in Medicare HMOs may disproportionately attract persons with vision problems. Also, incidence rates in this study are conditional on the individual undergoing eye examination during the period. Persons who chose not to be examined might have been less likely to have specific eye diseases. On balance, the selection effect due to HMO membership is likely much smaller than is selection due to eye examinations, because enrollment in HMOs was less than 20% and in the earlier years much less than this. Our sensitivity analysis indicates a substantial reduction in rates by using the assumption that the incident rate in the unexamined is only half that in the examined population. Such an assumption is likely to be warranted more in the case of DR and ARMD than in the case of glaucoma. With DR and ARMD, the macula and central vision are commonly affected relatively early in the disease course, so patients are likely to come in for eye examinations. Thus, those not coming in for eye examinations could be less likely to have the condition. Our alternative lower-bound rates reduce our incidence rates and make our estimates more comparable with those of previous studies. Glaucoma, on the other hand, less often has visual symptoms early in the course of disease. Although au- 1467
7 thors of a recent article emphasized that symptoms are common at initial examination for diagnosis, 25 no controlled study has been performed to assess symptoms in general among all patients seeking examination. Thus, we cannot assume that beneficiaries would notice glaucoma symptoms enough to schedule an examination. Nevertheless, the rates of glaucoma we found in this representative sample of Medicare beneficiaries are appreciably higher than those in population-based studies. Even the sensitivity analysis estimates were higher than published rates, except for the Melbourne study. 16 High incidence rates in all 3 diseases emphasize the benefit of regular eye examinations in this vulnerable population. For example, the incidence of diabetes mellitus in general is increasing. 26,27 Thus, the number of potential complications to be monitored is also increasing. The large Medicare database is an excellent source of information about chronic disease incidence, given the similarity of the estimates to known population-based study estimates. In particular, conditions with well-defined and standardized diagnostic criteria, such as DR, appear to be well-suited for estimating disease incidence and complementing the results of population-based studies. For conditions or population segments in which the incidence rates are too low on an annual basis to allow for economically viable study on a population basis, longitudinal claims analysis may provide an important information source. For conditions in which the diagnostic criteria are not well established in a meaningful way, such as glaucoma, substantial differences may exist between claims-based estimates and population-based studies that use stricter definitions. Estimates of incidence rates of glaucoma in the population-based studies may well be higher and similar to those of our analyses if their definitions included cases of ocular hypertension or those with merely suspiciouslooking optic nerves. 28 Eye care is unusual within medicine and health care in that it has several excellent population-based studies of the incidence of the major eye diseases. However, data about less common conditions are lacking, and estimates are subject to variation in precision because of the usually small sample sizes of population-based studies. The potential benefit of large representative claims databases, such as Medicare s, is a much larger sample size in a national cohort of individuals and a long follow-up. The calculation of population-level incidence rates depends in large part on the extent to which disease incidence is reflected in provider contacts. Estimating the number of undiagnosed cases among persons with no provider contact is the greatest challenge. Another challenge for the provider community is to use more specific criteria for the diagnosis of conditions to ensure that we all describe the same condition. Submitted for publication September 24, 2002; final revision received April 1, 2003; accepted June 8, This study was supported in part by grant RO1-AG from the National Institute on Aging, Bethesda, Md, and by a Lew Wasserman Merit Award (Dr Lee) from Research to Prevent Blindness, New York, NY. Corresponding author and reprints: Frank A. Sloan, PhD, Center for Health Policy, Law, and Management, Box 90253, Duke University, Durham, NC ( fsloan@ hpolicy.duke.edu). REFERENCES 1. Klein R, Klein BEK, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology. 1997;104: Mitchell P, Wang JJ, Foran S, Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology. 2002;109: Leske MC, Connell AM, Wu SY, et al. Incidence of open-angle glaucoma: the Barbados Eye Studies: the Barbados Eye Studies Group. Arch Ophthalmol. 2001; 119: Wu SY, Nemesure B, Leske MC. Observed versus indirect estimates of openangle glaucoma. Am J Epidemiol. 2001;153: Klein R, Klein BEK, Moss SC, Davis MD, De Mets DL. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol. 1989;107: Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA. Longitudinal prevalence of major eye diseases. Arch Ophthalmol. 2003;121: American Academy of Ophthalmology. Preferred Practice Pattern: Diabetic Retinopathy. San Francisco, Calif: American Academy of Ophthalmology; American Academy of Ophthalmology. Preferred Practice Pattern: Glaucoma.San Francisco, Calif: American Academy of Ophthalmology; American Academy of Ophthalmology. Preferred Practice Pattern: Age-related Macular Degeneration, Limited Revision. San Francisco, Calif: American Academy of Ophthalmology; American Diabetes Association. Diabetic retinopathy. Diabetes Care. 2002;25 (suppl 1):S90-S93. Available at: /25/suppl_1/s90. Accessed September 2, Nielsen NV. Diabetic retinopathy I: the course of retinopathy in insulin-treated diabetics: a one year epidemiological cohort study of diabetes mellitus: the Island of Falster, Denmark. Acta Ophthalmol (Copenh). 1984;62: Nielsen NV. Diabetic retinopathy II: the course of retinopathy in diabetics treated with oral hypoglycemic agents and diet regime alone: a one year epidemiological cohort study of diabetes mellitus: the Island of Falster, Denmark. Acta Ophthalmol (Copenh). 1984;62: Tudor SM, Hamman RF, Baron A, Johnson DW, Shetterly SM. Incidence and progression of diabetic retinopathy in Hispanics and non-hispanic whites with type 2 diabetes: San Luis Valley Diabetes Study, Colorado. Diabetes Care. 1998;21: Pogdor MJ, Leske MC, Ederer F. Incidence estimates for lens changes, macular changes, open-angle glaucoma, and diabetic retinopathy. Am J Epidemiol. 1983; 118: Lee VS, Kingsley RM, Lee ET, et al. The diagnosis of diabetic retinopathy: ophthalmoscopy versus fundus photography. Ophthalmology. 1993;100: Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the Visual Impairment Project. Ophthalmology. 2002;109: Bohn RL, Gurwitz JH, Yeomans SM, et al. Which patients are treated for glaucoma? An observational analysis. J Glaucoma. 2000;9: Klaver CC, Assink JJ, van Leeuwen R, et al. Incidence and progression rates of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci. 2001; 42: Maciejewski ML, Dowd B, Call KT, Feldman R. Comparing mortality and time until death for Medicare HMO and FFS beneficiaries. Health Serv Res. 2001;35: US General Accounting Office. Medicare: Fewer and Lower Cost Beneficiaries With Chronic Conditions Enroll in HMOs: Report to the Chairman, Subcommittee on Health, Committee on Ways and Means, US House of Representatives, August Available at: Accessed September 2, Shaefer E, Reschovsky JD. Are HMO enrollees healthier than others? Results from the community tracking study. Health Aff (Millwood). 2002;21: Taylor AK, Beauregard KM, Vistnes JP. Who belongs to HMOs: a comparison of fee-for-service versus HMO enrollees. MCRR. 1995;52: McFarland BH, Freeborn DK, Mullooly JP, Pope CR. Utilization patterns and mortality of HMO enrollees. Med Care. 1986;24: Blumberg MS. Health status and health care use by type of private health coverage. Milbank Mem Fund Q Health Soc. 1980;58: Janz NK, Wren PA, Lichter PR, et al. Quality of life in newly diagnosed glaucoma patients: the Collaborative Initial Glaucoma Treatment Study. Ophthalmology. 2001; 108: US Centers for Disease Control and Prevention. Trends in the prevalence and incidence of self-reported diabetes mellitus United States, MMWR Morb Mortal Wkly Rep. 1997;46: Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286: Leske MC, Connel AMS, Schachat AP, Hyman L. The Barbados Eye Study: prevalence of open angle glaucoma. Arch Ophthalmol. 1994;112:
LIMITED EVIDENCE IS AVAILable
EPIDEMIOLOGY Changes in Incidence of Diabetes Mellitus Related Eye Disease Among US Elderly Persons, -2005 Frank A. Sloan, PhD; Daniel Belsky, BA; David Ruiz Jr, BS; Paul Lee, MD, JD Objectives: To determine
More informationSupplementary Online Content
Supplementary Online Content Lin H-C, Stein JD, Nan B, et al. Association of geroprotective effects of metformin and risk of open-angle glaucoma in persons with diabetes mellitus. JAMA Ophthalmol. Published
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationUse of eye care services by people with diabetes: the Melbourne Visual Impairment Project
410 Department of Ophthalmology, University of Melbourne, Melbourne, Australia C A McCarty C W Lloyd-Smith P M Livingston Y L Stanislavsky H R Taylor Victorian WorkCover Authority, Melbourne, Australia
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY. MEASURE TYPE: Process
Quality ID #14 (NQF 0087): Age-Related Macular Degeneration (AMD): Dilated Macular Examination National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY
More informationRetinopathy in a diabetic population
Kathmandu University Medical Journal (2007), Vol. 5, No. 2, Issue 18, 204-209 Retinopathy in a diabetic population Shrestha S 1, Malla OK 2, Karki DB 3, Byanju RN 4 2 Fellow of NAMS, 3 Professor, NAMS,
More informationChapter 2: Identification and Care of Patients with CKD
Chapter 2: Identification and Care of Patients with CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationDisparities in Vison Loss and Eye Health
Disparities in Vison Loss and Eye Health Xinzhi Zhang, MD, PhD, FACE, FRSM National Institute on Minority Health and Health Disparities National Institutes of Health Disclaimer The findings and conclusions
More informationPrevalence Of Primary Open Angle Glaucoma in Diabetic Patients
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. III (June. 2017), PP 147-151 www.iosrjournals.org Prevalence Of Primary Open Angle Glaucoma
More informationDiabetes, particularly diabetic retinopathy, is
Chapter 14 Vision Disorders in Diabetes Ronald Klein, MD, MPH, and Barbara E.K. Klein, MD, MPH SUMMARY Diabetes, particularly diabetic retinopathy, is the leading cause of new cases of blindness in people
More informationPrevalence estimates indicate the burden of a condition (e.g.,
Special Issue The alence of Age-Related Eye Diseases and Visual Impairment in Aging: Current Estimates Ronald Klein and Barbara E. K. Klein Department of Ophthalmology and Visual Sciences, University of
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With CKD Over half of patients in the Medicare 5% sample (aged 65 and older) had at least one of three diagnosed chronic conditions chronic kidney disease
More informationIncidence of manifest glaucoma
Incidence of manifest glaucoma BO BENGTSSON British Journal of Ophthalmology, 1989, 73, 483-487 From the Departments ofresearch in Primary Health Care and Experimental Ophthalmology, University of Lund,
More informationDr Taha Abdel Monein Labib Professor of Eye Surgery Cairo University.
Dr Taha Abdel Monein Labib Professor of Eye Surgery Cairo University. Although the clinical picture of glaucoma is well described, the exact mechanism leading to this specific type of damage to the optic
More informationDiabetes in Manitoba: Trends among Adults
Diabetes Among Adults in Manitoba (1989-2013) Diabetes in Manitoba: Trends among Adults 1989-2013 1989-2013 Epidemiology & Surveillance Active Living, Population and Public Health Branch Manitoba Health,
More informationThe treatment benefit of latanoprost has not been studied in the following populations/patients:
6.1. ELEMENTS FOR A PUBLIC SUMMARY 6.1.1. Overview of Disease Epidemiology Glaucoma is the second leading cause of blindness worldwide, and affects about 66.8 million people worldwide i,ii. Glaucoma can
More informationSOCIOECONOMICS AND HEALTH SERVICES SECTION EDITOR: PAUL P. LEE, MD
SOCIOECONOMICS AND HEALTH SERVICES SECTION EDITOR: PAUL P. LEE, MD Racial Disparities in the Use of Ancillary Testing to Evaluate Individuals With Open-Angle Glaucoma Joshua D. Stein, MD, MS; Nidhi Talwar,
More informationChapter 2: Identification and Care of Patients With CKD
Chapter 2: Identification and Care of Patients With Over half of patients from the Medicare 5% sample (restricted to age 65 and older) have a diagnosis of chronic kidney disease (), cardiovascular disease,
More informationMEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND PACHYMETRY. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND,, PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationand at the same patient encounter. Code has been deleted. For scanning computerized ophthalmic diagnostic imaging of optic nerve and retin
92227: Remote imaging for detection of retinal disease (eg, retinopathy in a patient with diabetes) with analysis and report under physician supervision, unilateral or bilateral. For Medicare, bill only
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 6: Medicare Expenditures for Persons With CKD Medicare spending for patients with CKD aged 65 and older exceeded $50 billion in 2013, representing 20% of all
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationStudy of correlation of severity of diabetic retinopathy with levels of haemogloelbin A1c in patients with type II Diabetes Mellitus
Original article: Study of correlation of severity of diabetic retinopathy with levels of haemogloelbin A1c in patients with type II Diabetes Mellitus 1Dr Apoorva*, 2 Dr Sabhia Jan 1Senior Resident, 2
More informationClinical Policy: Implantable Miniature Telescope for Age Related Macular Degeneration Reference Number: CP.MP.517
Clinical Policy: Implantable Miniature Telescope for Age Related Macular Reference Number: CP.MP.517 Effective Date: 11/16 Last Review Date: 11/17 See Important Reminder at the end of this policy for important
More informationRANZCO Screening and Referral Pathway for Diabetic Retinopathy #
RANZCO Screening and Referral Pathway for Diabetic Retinopathy # Patient Presents a. Screen for Diabetic Retinopathy every 2 years b. Begin screening at diagnosis of Diabetes * Clinical Modifi ers Yearly
More informationDiabetic retinopathy in Victoria, Australia: the Visual Impairment Project
Br J Ophthalmol 2000;84:865 870 865 Centre for Eye Research Australia, University of Melbourne, Melbourne, Australia R McKay C A McCarty H R Taylor Correspondence to: Cathy McCarty, Centre for Eye Research
More informationOptic Disc Cupping: Four Year Follow-up from the WESDR
Investigative Ophthalmology & Visual Science, Vol. 30, o., February 989 Copyright Association for Research in Vision and Ophthalmology Optic Disc Cupping: Four Year Follow-up from the WER Barbara E. K.
More informationAbstract. Introduction. Original paper. Comparison of screening for diabetic retinopathy by non-specialists and specialists
Comparison of screening for diabetic retinopathy by non-specialists and specialists Effectiveness of screening for diabetic retinopathy by nonspecialist doctors: the importance of physician-ophthalmologist
More informationLongitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme
(2002) 16, 140 145 2002 Nature Publishing Group All rights reserved 1470-269X/02 $25.00 www.nature.com/eye CLINICAL STUDY Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic
More informationChapter 3: Morbidity and Mortality in Patients with CKD
Chapter 3: Morbidity and Mortality in Patients with CKD In this 2017 Annual Data Report (ADR) we introduce analysis of a new dataset. To provide a more comprehensive examination of morbidity patterns,
More informationVeteran Eye Disease After Eligibility Reform: Prevalence and Characteristics
MILITARY MEDICINE, 178, 7:811, 2013 Veteran Eye Disease After Eligibility Reform: Prevalence and Characteristics April Y. Maa, MD*; Centrael Evans, BSc ; William Delaune, PhD ; Mary G. Lynch, MD* ABSTRACT
More informationReport for EYEGENETIX. Prepared on. May 24, By: David Davis, CPC, CPC-H, CCC (Ret.)
Report for EYEGENETIX Prepared on May 24, 2016 By: David Davis, CPC, CPC-H, CCC (Ret.) EyeGenetix EyeGenetix sells ophthalmic diagnostic equipment to primary care providers. This equipment performs the
More informationControlled IOP Uncontrolled IOP Diabetes with or without retinopathy
PQRS Guidelines I. Introduction A. The reporting of these additional codes are used to determine the quality of care a provider gives to patients with certain diseases. B. All PQRS codes including the
More informationTable of Contents. Page 2 of 20
Page 1 of 20 Table of Contents Table of Contents... 2 NMHCTOD Participants... 3 Introduction... 4 Methodology... 5 Types of Data Available... 5 Diabetes in New Mexico... 7 HEDIS Quality Indicators for
More informationThe Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care
The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Medical Retina November 2016 Association of Health Professions in Ophthalmology General basic
More informationChapter 5: Acute Kidney Injury
Chapter 5: Acute Kidney Injury Introduction In recent years, acute kidney injury (AKI) has gained increasing recognition as a major risk factor for the development of chronic kidney disease (CKD). The
More informationBehavioral Health Hospital and Emergency Department Health Services Utilization
Behavioral Health Hospital and Emergency Department Health Services Utilization Rhode Island Fee-For-Service Medicaid Recipients Calendar Year 2000 Prepared for: Prepared by: Medicaid Research and Evaluation
More informationPublished Examination-based Prevalence of Major Eye Disorders
Published Examination-based Prevalence of Major Eye Disorders JUNE 22, 218 Prepared by: Michelle Dougherty, John Wittenborn, Emily Phillips, NORC at the University of Chicago Bonnielin Swenor, Johns Hopkins
More informationORIGINAL INVESTIGATION. Longitudinal Incidence and Prevalence of Adverse Outcomes of Diabetes Mellitus in Elderly Patients
ORIGINAL INVESTIGATION Longitudinal Incidence and Prevalence of Adverse Outcomes of Diabetes Mellitus in Elderly Patients M. Angelyn Bethel, MD; Frank A. Sloan, PhD; Daniel Belsky, BA; Mark N. Feinglos,
More informationLong-Term Visual Outcome in Proliferative Diabetic Retinopathy Patients After Panretinal Photocoagulation
Long-Term Visual Outcome in Proliferative Diabetic Retinopathy Patients After Panretinal Photocoagulation Murat Dogru, Makoto Nakamura, Masanori Inoue and Misao Yamamoto Department of Ophthalmology, Kobe
More informationDiabetes Care 24: , 2001
Pathophysiology/Complications O R I G I N A L A R T I C L E Prevalence and Significance of Retinopathy in Subjects With Type 1 Diabetes of Less Than 5 Years Duration Screened for the Diabetes Control and
More informationStudy of 189 Cases of Diabetic Retinopathy at CMC Larkana
Original Article Study of 189 Cases of Diabetic Retinopathy at CMC Larkana Shahid Jamal Siddiqui, Sayed Imtiaz Ali Shah, Abdul Qadir Shaikh, Mohammed Yousuf Depar, Safder Ali Abbassi Pak J Ophthalmol 2007,
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority
Quality ID #191 (NQF 0565): Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management
More informationLandmark Tube Trials
SECTION EDITOR: BARBARA SMIT, MD, PhD Landmark Tube Trials A review of key findings from recent multicenter randomized clinical trials involving tube shunts. BY AMBIKA HOGUET, MD, AND STEVEN J. GEDDE,
More informationVision and Eye Health Surveillance
Vision and Eye Health Surveillance Panel moderator: Jeff Todd, Prevent Blindness 500 Cities: Local Data for Better Health Measures Tracked UNHEALTHY BEHAVIORS Binge Drinking Current Smoking No Leisure
More informationOphthalmology. Ophthalmology Services
Ophthalmology Ophthalmology Services The Ophthalmology service offers the latest and most comprehensive eye care for patients. With a dedicated team of eye surgeons and consultants, we treat vision problems
More informationVisual prognosis after panretinal photocoagulation for. Proliferative diabetic retinopathy (PDR)
Visual prognosis after panretinal photocoagulation for proliferative diabetic retinopathy Toke Bek 1 and Mogens Erlandsen 2 1 Department of Ophthalmology, A rhus University Hospital, A rhus, Denmark 2
More informationDiabetes. Health Care Disparities: Medical Evidence. A Constellation of Complications. Every 24 hours.
Health Care Disparities: Medical Evidence Diabetes Effects 2.8 Million People in US 7% of the US Population Sixth Leading Cause of Death Kenneth J. Steier, DO, MBA, MPH, MHA, MGH Dean of Clinical Education
More informationPresent relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS.
Course title: The Glaucoma Compass Course length: 1 hour +/- 31 slides Corse Description: Even with the technology and available information, glaucoma decision making can still be confusing. How should
More informationNote: This is an outcome measure and will be calculated solely using registry data.
Quality ID #385: Adult Primary Rhegmatogenous Retinal Detachment Surgery: Visual Acuity Improvement Within 90 Days of Surgery National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR
More informationJMSCR Vol. 03 Issue 08 Page August 2015
www.jmscr.igmpublication.org Impact Factor 3.79 ISSN (e)-2347-176x DOI: http://dx.doi.org/10.18535/jmscr/v3i8.05 Study of Prevalence of Diabetic Retinopathy in Already Confirmed Diabetic Patients Who Were
More informationEye Care and Ear, Nose and Throat Conditions
Eye Care and Ear, Nose and Throat Conditions DRAFT REPORT FOR COMMENT July 10, 2015 This report is funded by the Department of Health and Human Services under contract HHSM-500-2012-00009I Task Order HHSM-500-T0008
More informationRetinal Nerve Fiber Layer Measurements in Myopia Using Optical Coherence Tomography
Original Article Philippine Journal of OPHTHALMOLOGY Retinal Nerve Fiber Layer Measurements in Myopia Using Optical Coherence Tomography Dennis L. del Rosario, MD and Mario M. Yatco, MD University of Santo
More informationNote: This is an outcome measure and will be calculated solely using registry data.
Measure #303 (NQF 1536): Cataracts: Improvement in Patient s Visual Function within 90 Days Following Cataract Surgery National Quality Strategy Domain: Person and Caregiver-Centered Experience and Outcomes
More informationEPIDEMIOLOGY AND BIOSTATISTICS
Incidence of Open-Angle Glaucoma The Barbados Eye Studies EPIDEMIOLOGY AND BIOSTATISTICS M. Cristina Leske, MD, MPH; Anthea M. S. Connell, FRCS, FRCOphth; Suh-Yuh Wu, MA; Barbara Nemesure, PhD; Xiaowei
More informationEye Care and Ear, Nose, and Throat Conditions,
Eye Care and Ear, Nose, and Throat Conditions, 2014-2016 FINAL TECHNICAL REPORT February 29, 2016 This report is funded by the Department of Health and Human Services under contract HHSM-500-2012-00009I
More informationClinical biomicroscopy versus fluorescein angiography: Effectiveness and sensitivity in detecting diabetic retinopathy
European Journal of Ophthalmology / Vol. 17 no. 1, 2007 / pp. 84-88 Clinical biomicroscopy versus fluorescein angiography: Effectiveness and sensitivity in detecting diabetic retinopathy S.S. KHALAF, M.D.
More informationNote: This is an outcome measure and will be calculated solely using registry data.
Quality ID #303 (NQF 1536): Cataracts: Improvement in Patient s Visual Function within 90 Days Following Cataract Surgery National Quality Strategy Domain: Person and Caregiver-Centered Experience and
More informationNOA 3rd Party Newsletter PQRS EDITION - Page 1 CONTENTS. Traffic Sheet P.3. Flowsheet & Detailed Directions P.11.
NOA 3rd Party Newsletter - 2016 PQRS EDITION - Page 1 CONTENTS EYE MEASURES Measure #12 :Primary Open-Angle Glaucoma: Optic Nerve Evaluation Traffic Sheet P.2. Flowsheet & Detailed Directions P.8. Measure
More informationAge-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR)
Preserve Vision Information Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Regular examination by your ophthalmologist will allow early detection and treatment. Age-related Macular
More informationmedicaid and the The Role of Medicaid for People with Diabetes
on medicaid and the uninsured The Role of for People with Diabetes November 2012 Introduction Diabetes is one of the most prevalent chronic conditions and a leading cause of death in the United States.
More informationDR Screening In Singapore: Achievements & Future Challenges
DR Screening In Singapore: Achievements & Future Challenges Ecosse Lamoureux Director, Population Research Platform Singapore Eye Research Institute (SERI) Background About 600,000 of Singaporeans aged
More informationImplementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute
Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates McGreal Educational Institute Excellence in Optometric Education John A. McGreal Jr., O.D. Missouri Eye Associates
More information5. MEDICARE COVERAGE OF SCREENING FOR OPEN-ANGLE GLAUCOMA. Costs to Medicare
5. MEDICARE COVERAGE OF SCREENING FOR OPEN-ANGLE GLAUCOMA Costs to Medicare At present, neither screening for all people with high intraocular pressure (IOP) nor for those with only manifest open-angle
More informationIntravitreal Avastin (Bevacizumab)
Intravitreal Avastin (Bevacizumab) Date of Origin: 10/18/2018 Last Review Date: 10/18/2018 Effective Date: 10/18/2018 Dates Reviewed: 10/2018 Developed By: Medical Criteria Committee I. Length of Authorization
More informationInsurance Providers Reduce Diabetes Risk Through CDC Program
Insurance Providers Reduce Diabetes Risk Through CDC Program ISSUE BRIEF JULY 2018 KEY TAKEAWAYS 86 million Americans 1 in 3 adults have pre-diabetes. Studies show that losing 5 to 7 percent of body weight
More informationImplementing New & Revised ICD-10 Codes
Implementing New & Revised ICD-10 Codes John A. McGreal Jr., O.D. Missouri Eye Associates cgreal Educational Institute Excellence in Optometric Education John A. McGreal Jr., O.D. Missouri Eye Associates
More informationAssociation of grade of cataract with duration of diabetes, age and gender in patients with type II diabetes mellitus
International Journal of Advances in Medicine Lathika VK et al. Int J Adv Med. 2016 May;3(2):304-308 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20161080
More informationPrevalence of age related maculopathy in a representative Japanese population: the Hisayama study
Br J Ophthalmol 2001;85:1153 1157 1153 WORLD VIEW (Series editor: Emmett T Cunningham Jr) Department of Ophthalmology, Faculty of Medicine, Kyushu University, Fukuoka, Japan Y Oshima T Ishibashi T Murata
More informationHEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES
HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES Presented by Parul Agarwal, PhD MPH 1,2 Thomas K Bias, PhD 3 Usha Sambamoorthi,
More informationOnline Supplementary Material
Section 1. Adapted Newcastle-Ottawa Scale The adaptation consisted of allowing case-control studies to earn a star when the case definition is based on record linkage, to liken the evaluation of case-control
More informationThe CSAC will review recommendations from the Eye Care and Ear, Nose and Throat (EENT) Conditions project at its October 13 conference call.
TO: FR: Consensus Standards Approval Committee (CSAC) EENT Project Team RE: Eye Care and Ear, Nose and Throat Conditions Member Voting Results DA: October 13, 2015 The CSAC will review recommendations
More informationINFANTS WITH birth weights less
CLINICAL SCIENCES of Retinopathy of Prematurity Michael X. Repka, MD; Earl A. Palmer, MD; Betty Tung, MS; for the Cryotherapy for Retinopathy of Prematurity Cooperative Group Objective: To report the timing
More informationDr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding
Dr. Harvey Richman, OD, FAAO, FCOVD Diplomate American Board of Optometry Executive Committee AOA Third Party Center Founder Ask the AOA Coding Experts 92000 Codes Special Ophthalmological Services Describe
More informationProgression of diabetic retinopathy after cataract extraction
BritishlournalofOphthalmology, 1991,75,547-551 Ophthalmology Department, Kaplan Hospital, Rehovot, affiliated with the Hebrew University-Hadassah Medical School, Jerusalem, Israel A Pollock S Dotan M Oliver
More informationChapter 1: CKD in the General Population
Chapter 1: CKD in the General Population Overall prevalence of CKD (Stages 1-5) in the U.S. adult general population was 14.8% in 2011-2014. CKD Stage 3 is the most prevalent (NHANES: Figure 1.2 and Table
More informationDiabetic retinopathy is the
ORIGINAL ARTICLES Digital Retinal Imaging in a Residencybased Patient-centered Medical Home Robert Newman, MD; Doyle M. Cummings, PharmD; Lisa Doherty, MD, MPH; Nick R. Patel, MD BACKGROUND AND OBJECTIVES:
More informationEylea (aflibercept) Document Number: IC-0026
Eylea (aflibercept) Document Number: IC-0026 Last Review Date: 3/1/2018 Date of Origin: 02/07/2013 Dates Reviewed: 03/07/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 04/2015,
More informationORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths
ORIGINAL INVESTIGATION Effects of Prehypertension on Admissions and Deaths A Simulation Louise B. Russell, PhD; Elmira Valiyeva, PhD; Jeffrey L. Carson, MD Background: The Joint National Committee on Prevention,
More informationDiabetic Retinopathy
Diabetic Retinopathy Overview This presentation covers the following topics: Definitions Epidemiology of diabetic retinopathy Evidence for public health approaches Screening for diabetic retinopathy Health
More information2017 USRDS ANNUAL DATA REPORT KIDNEY DISEASE IN THE UNITED STATES S611
Healthy People 2020 In this chapter, we examine data for 11 Healthy People 2020 (HP2020) objectives 10 for CKD and one for diabetes spanning 20 total indicators for which the USRDS serves as the official
More informationTITLE: Outcomes of Screening Mammography in Elderly Women
AD Award Number: DAMD17-00-1-0193 TITLE: Outcomes of Screening Mammography in Elderly Women PRINCIPAL INVESTIGATOR: Philip W. Chu Rebecca Smith-Bindman, M.D. CONTRACTING ORGANIZATION: University of California,
More informationFor details on measurement and recording of visual acuity, refer to Annex 1. VISION INTERPRETING RESULTS ABSTRACT
management update on functional decline in older adults 2012 Unit No. 5 VISION Dr Au Eong Kah Guan, Ms Yulianti, Ms Fifiana ABSTRACT Among Singaporean adults of Chinese origin aged 40 to 79 years old,
More informationCorrelation between vision- and health-related quality of life scores
Correlation between - and -related quality of life s Brighu N. Swamy, 1 Ee-Munn Chia, 1 Jie Jin Wang, 1,2 Elena Rochtchina 1 and Paul Mitchell 1 1 Centre for Vision Research, Department of Ophthalmology
More informationDiabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec
RUIS McGILL VIRTUAL HEALTH AND SOCIAL SERVICES CENTRE (CvSSS) SIMPLIFYING TELEHEALTH! Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec Nurse and Imager Training Prepared
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationEPIDEMIOLOGY AND BIOSTATISTICS. Age-Specific Prevalence and Causes of Blindness and Visual Impairment in an Older Population
Age-Specific Prevalence and Causes of Blindness and Visual Impairment in an Older Population The Rotterdam Study EPIDEMIOLOGY AND BIOSTATISTICS Caroline C. W. Klaver, MD; Roger C. W. Wolfs, MD; Johannes
More informationManual. Manual Welsh Eye Care Initiative. A Welsh Eye Care Initiative. Protocol. The Assessment and Management of Age-related Macular Degeneration
A Protocol 1.0 Definitions The following terms are important in this text: Wet Macular Degeneration Condition caused by the growth of abnormal blood vessels under the retina. Symptoms appear suddenly and
More informationElderly people need an eye examination before entering nursing homes
Dan Med J 64/2 February 217 danish medical JOURNAL 1 Elderly people need an eye examination before entering nursing homes Hanne Jensen 1 & Gitte Tubæk 2 Abstract Introduction: It is well documented that
More informationTHE ECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN A WORKING AGE AND COMMERCIALLY INSURED POPULATION. Christopher John Wallick
THE ECONOMIC BURDEN OF DIABETIC MACULAR EDEMA IN A WORKING AGE AND COMMERCIALLY INSURED POPULATION Christopher John Wallick A thesis submitted in partial fulfillment of the requirements for the degree
More informationVision Research & Clinical Trials Havener Eye Institute Jenna Rajczyk Demarcus Williams 13 April 2018
Vision Research & Clinical Trials Havener Eye Institute Jenna Rajczyk Demarcus Williams 13 April 2018 Our Journey to Clinical Research Types of Research Animal Behavioral Basic/Fundamental Translational
More informationSupplementary Online Content
Supplementary Online Content Jain A, Marshall J, Buikema A, et al. Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA. doi:10.1001/jama.2015.3077
More informationMedicare Risk Adjustment for the Frail Elderly
Medicare Risk Adjustment for the Frail Elderly John Kautter, Ph.D., Melvin Ingber, Ph.D., and Gregory C. Pope, M.S. CMS has had a continuing interest in exploring ways to incorporate frailty adjustment
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationTHE PREVALENCE OF CAUSES FOR DIABETIC RETINOPATHY USING MATHEMATICAL MODELS
International Journal of Advanced Research in Engineering and Technology (IJARET) Volume 9, Issue 6, November-December 2018, pp. 167 171, Article ID: IJARET_09_06_017 Available online at http://www.iaeme.com/ijaret/issues.asp?jtype=ijaret&vtype=9&itype=6
More informationTotal financial cost to the U.S. Direct medical costs: Direct non-medical costs: Productivity losses: TOTAL: $16.2 billion $11.2 billion $8.
2 Annual Total Burden to the U.S. Economy of AMD, Cataract, Diabetic Retinopathy, Glaucoma, Refractive Errors, Visual Impairment and Blindness Total financial cost to the U.S. For the year 24, the total
More informationAge-related maculopathy and cataract surgery outcomes: visual acuity and healthrelated. life CLINICAL STUDY
(2007) 21, 324 330 & 2007 Nature Publishing Group All rights reserved 0950-222X/07 $30.00 www.nature.com/eye CLINICAL STUDY Age-related maculopathy and cataract surgery outcomes: visual acuity and healthrelated
More informationMeasure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care
Measure #117 (NQF 0055): Diabetes: Eye Exam National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS F INDIVIDUAL MEASURES: CLAIMS, REGISTRY DESCRIPTION: Percentage of patients 18-75
More information2016 VSP Summary Data Report
2016 VSP Summary Data Report For the Vision & Eye Health Surveillance System DATE JUNE 20, 2018 PRESENTED TO: Jinan Saaddine, Division of Diabetes Translation, Centers for Disease Control and Prevention
More informationAmin Aboali Hassan. Department Of Ophthalmology, Sohag University Hospital, Faculty of Medicine, Sohag University, Egypt
Three -Year Incidence and Risk Factors for Retinal Vein Occlusion in Sohag University Hospital Amin Aboali Hassan Department Of Ophthalmology, Sohag University Hospital, Faculty of Medicine, Sohag University,
More information